CG
ALNY icon

Cutler Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cutler Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,500
Closed -$265K – 3562
2023
Q3 		$265K Buy
+1,500
New +$286K 0.03% 641
2023
Q2 		– Sell
-600
Closed -$120K – 3511
2023
Q1 		$120K Buy
+600
New +$126K 0.01% 898
2022
Q1 		– Sell
-11,582
Closed -$1.76M – 5241
2021
Q4 		$1.96M Buy
+11,582
New +$2.15M 0.08% 258
2021
Q3 		– Sell
-1,200
Closed -$203K – 5635
2021
Q2 		$203K Buy
+1,200
New +$176K 0.01% 1335
2020
Q1 		– Sell
-3,900
Closed -$450K – 3955
2019
Q4 		$449K Buy
3,900
+363
+10% +$36.2K 0.03% 485
2019
Q3 		$284K Sell
3,537
-1,900
-35% -$150K 0.03% 548
2019
Q2 		$394K Buy
5,437
+2,937
+117% +$225K 0.04% 407
2019
Q1 		$233K Sell
2,500
-175
-7% -$14.6K 0.02% 585
2018
Q4 		$195K Sell
2,675
-206
-7% -$15.8K 0.02% 651
2018
Q3 		$252K Sell
2,881
-900
-24% -$90.5K 0.02% 727
2018
Q2 		$372K Sell
3,781
-910
-19% -$90.3K 0.03% 543
2018
Q1 		$558K Sell
4,691
-39,944
-89% -$5.15M 0.05% 378
2017
Q4 		$5.67M Buy
44,635
+1,876
+4% +$236K 0.23% 54
2017
Q3 		$5.02M Buy
42,759
+12,471
+41% +$1.06M 0.19% 77
2017
Q2 		$2.42M Buy
30,288
+4,128
+16% +$264K 0.09% 184
2017
Q1 		$1.34M Buy
26,160
+6,728
+35% +$311K 0.06% 287
2016
Q4 		$727K Buy
19,432
+6,882
+55% +$288K 0.03% 532
2016
Q3 		$850K Sell
12,550
-4,535
-27% -$320K 0.04% 393
2016
Q2 		$948K Buy
17,085
+12,529
+275% +$789K 0.05% 304
2016
Q1 		$285K Buy
4,556
+2,538
+126% +$169K 0.02% 800
2015
Q4 		$189K Buy
+2,018
New +$187K 0.01% 1223

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Cutler Group's ALNY Position: Q4 2023 in Review

Cutler Group sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 1,500 shares — an estimated $265K sold.

Cutler Group first reported a position in ALNY in Q4 2015 and held it in 21 quarters. The position peaked at $5.67M in Q4 2017. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

  • Cutler Group reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 1,500 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $265K.
  • Cutler Group first reported a position in Alnylam Pharmaceuticals in Q4 2015 and held it in 21 quarters.
  • Cutler Group's Alnylam Pharmaceuticals position peaked at $5.67M in Q4 2017.
  • 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.